๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Grip force abnormalities in de novo Parkinson's disease

โœ Scribed by Stuart J. Fellows; Johannes Noth

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
533 KB
Volume
19
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

โœฆ Synopsis

Abstract

In recent years it has been shown that a variety of movement disorders are associated with abnormalities of the fine motor control of the hand. In Parkinson's disease (PD), these changes consist of a slowing of the rate of grip force development and the use of abnormally large grip forces both during lifting and static holding of an object. It has been suggested, however, that these changes are a direct effect of the patient's levodopa medication or associated with levodopa induced dyskinesias. Accordingly, we examined the performance of de novo Parkinson patients in a precision lifting task. All patients (n = 6) were newly diagnosed and showed rigidity, bradykinesia, or both, but were unaffected by tremor or dyskinesia. None of the patients had received antiparkinson medication. Grip force was abnormally high in both the lifting and hold phases. This exaggeration was equal in magnitude to that observed previously in medicated patients. Thus we conclude that the abnormalities in grip force observed here are intrinsic features of PD and not the result of dopamine medication or its side effects. ยฉ 2004 Movement Disorder Society

๐Ÿ“œ SIMILAR VOLUMES

Decision making in de novo Parkinson's d
Decision making in de novo Parkinson's disease
โœ Michele Poletti; Daniela Frosini; Claudio Lucetti; Paolo Del Dotto; Roberto Cera ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 87 KB

## Abstract The aim is to study decision making in patients with de novo Parkinson's disease (PD). Recent studies reported that medicated patients with PD have poor performances compared with ageโ€matched healthy controls in decision making tasks, specially in the Iowa Gambling Task. Two principal c

Mitochondrial abnormalities in Parkinson
Mitochondrial abnormalities in Parkinson's disease
โœ Yoshikuni Mizuno; Shin-Ichirou Ikebe; Nobutaka Hattori; Yuko Nakagawa-Hattori; M ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 130 KB ๐Ÿ‘ 1 views
Trial of subtherapeutic pergolide in de
Trial of subtherapeutic pergolide in de novo Parkinson's disease
โœ Katherine Grosset; Donald Grosset; Andrew Lees ๐Ÿ“‚ Article ๐Ÿ“… 2005 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 95 KB

## Abstract The effect of pergolide 25 ฮผg twice daily on levodopa initiation was assessed in a randomized, placeboโ€controlled, parallel group, doubleโ€blind multicenter trial in 106 untreated early Parkinson's disease patients. The primary endpoint of mean time until levodopa was 520 days (95% confi

Reward processing abnormalities in Parki
Reward processing abnormalities in Parkinson's disease
โœ Dimitrios Kapogiannis; Eric Mooshagian; Paul Campion; Jordan Grafman; Trelawny J ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 152 KB

## Abstract The primary motor cortex is important for motor learning and response selection, functions that require information on the expected and actual outcomes of behavior. Therefore, it should receive signals related to reward. Pathways from reward centers to motor cortex exist in primates. Pr

Excessive daytime sleepiness in de novo
Excessive daytime sleepiness in de novo and treated Parkinson's disease
โœ Giovanni Fabbrini; Piero Barbanti; Cinzia Aurilia; Nicola Vanacore; Caterina Pau ๐Ÿ“‚ Article ๐Ÿ“… 2002 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 65 KB ๐Ÿ‘ 1 views

## Abstract Excessive daytime sleepiness (EDS) in Parkinson's disease (PD) is due to either treatmentโ€related factors or the disease itself. The study of this disturbing phenomenon in de novo parkinsonian patients may contribute to a better understanding of its pathophysiology. We conducted a case